Home

Insights

PE

Metropolis Healthcare Ltd P/E Ratio

Metropolis Healthcare Ltd P/E Ratio

download
stocks purchased

₹ 0.3 Cr

Volume transacted

stocks purchased

1.4 K

stocks traded

Last Updated time: 16 Jul 13:14 PM

Image

Metropolis Healthcare Ltd

NSE: METROPOLIS

PE

83.1

Last updated : 16 Jul 13:14 PM

Key Highlights

    The P/E Ratio of Metropolis Healthcare Ltd is 83.1 as of 16 Jul 13:14 PM .a1#The P/E Ratio of Metropolis Healthcare Ltd changed from 51.1 on March 2019 to 44.8 on March 2023 . This represents a CAGR of -3.24% over 4 years. a1#The Latest Trading Price of Metropolis Healthcare Ltd is ₹ 2037 as of 16 Jul 13:07 .a1#The PE Ratio of Healthcare Industry has changed from 47.8 to 43.6 in 5 years. This represents a CAGR of -1.82%a1# The PE Ratio of Automobile industry is 17.2. The PE Ratio of Finance industry is 24.5. The PE Ratio of Healthcare industry is 54.4. The PE Ratio of IT - Software industry is 29.2. The PE Ratio of Retail industry is 143.1. The PE Ratio of Textiles industry is 12.1. In 2024a1#The Market Cap of Metropolis Healthcare Ltd changed from ₹ 6512 crore on March 2019 to ₹ 6395 crore on March 2023 . This represents a CAGR of -0.45% over 4 years. a1#The Revenue of Metropolis Healthcare Ltd changed from ₹ 282.9 crore to ₹ 333.54 crore over 8 quarters. This represents a CAGR of 8.58% a1#The EBITDA of Metropolis Healthcare Ltd changed from ₹ 71.53 crore to ₹ 82.52 crore over 8 quarters. This represents a CAGR of 7.41% a1#The Net Pr of Metropolis Healthcare Ltd changed from ₹ 33.56 crore to ₹ 36.53 crore over 8 quarters. This represents a CAGR of 4.33% a1#The Dividend Payout of Metropolis Healthcare Ltd changed from 75.83 % on March 2019 to 29.48 % on March 2023 . This represents a CAGR of -17.22% over 5 years. a1#

Open Demat Account

Lead form image

Enter your mobile no. to continue

+91

*By signing up you agree to our terms & conditions

50 Years

of Trust & Legacy

₹0 AMC

for First Year

₹0 Brokerage

on Delivery, Intraday, Currency and NSE F&O

×

Historical P/E Ratio of Metropolis Healthcare Ltd

The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share. P/E Ratio Formula P/E ratio = (CMP of share/ Earning per share) Types of Price to Earning Ratio 1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance. 2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.

Historical P/E Ratio of Metropolis Healthcare Ltd

Period
Mar '190
Mar '2051.1
Mar '2162.6
Mar '2248.7
Mar '2344.8

Company Fundamentals for Metropolis Healthcare Ltd

Market Cap

10,617 Cr

EPS

25.0

P/E Ratio (TTM) *

83.1

P/B Ratio (TTM) *

9.7

Day’s High

2080.95

Day’s Low

2030.05

DTE *

0.2

ROE *

11.7

52 Week High

2120.9

52 Week Low

1296.0

ROCE *

15.3

* All values are consolidated

Last Updated time: 16 Jul 13:14 PM

* All values are consolidated

Last Updated time: 16 Jul 13:14 PM

Image

Metropolis Healthcare Ltd

NSE: METROPOLIS

PRICE

2037.4

-35.25 (-1.70%)

stock direction

Last updated : 16 Jul 13:07

×

PRICE

The current market price or CMP refers to the price at which the securities are trading in the share market. Current price in Over-the-counter costs: The following current price depends upon the bid price & the asking price when a financial asset is sold over-the-counter(OTC). Current Price in Bond Market: The current price of a bond is determined by measuring the actual interest rate against the bid-related interest rate. The par or the face value is then calculated to represent the remaining interest payments due which occur before the maturity of the bond.

Share price Over Time

1M

1Y

3Y

5Y

* All values are in Rupees

SWOT Analysis Of Metropolis Healthcare Ltd

Strength

3

S

Weakness

2

W

Opportunity

0

O

Threats

1

T

BlinkX Score for Metropolis Healthcare Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

Asset Value vs Market Value of Metropolis Healthcare Ltd

Market Value

10,618

Asset Value

315

32.7 X

Value addition

* All values are in Rupees

Competitive Comparison of P/E Ratio

Company NamePEMarket Cap (INR Cr.)
Metropolis Healthcare Ltd8310,617
Apollo Hospitals Enterprise Ltd10392,637
Max Healthcare Institute Ltd8489,503
Fortis Healthcare Ltd6236,695
Global Health Ltd6832,523
Narayana Hrudayalaya Ltd3225,483

Key Valuation Metric of Metropolis Healthcare Ltd

Earnings

127 Cr

83.1 X

PE Ratio

Market Cap

₹10617Cr

PE Ratio

PS Ratio

PB Ratio

The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share.


P/E Ratio Formula


P/E ratio = (CMP of share/ Earning per share)


Types of Price to Earning Ratio


1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance.
2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.

Earnings

127 Cr

83.1 X

PE Ratio

Market Cap

₹10617Cr

PE Ratio

PS Ratio

PB Ratio

The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share.


P/E Ratio Formula


P/E ratio = (CMP of share/ Earning per share)


Types of Price to Earning Ratio


1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance.
2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.

PE Ratio of Healthcare Industry over time

PE Ratio of Top Sectors

×

Historical Market Cap of Metropolis Healthcare Ltd

Market Cap or market capitalisation refers to metrics that are used to measure a company's size. It is defined as the total market value of a company's outstanding shares of stock. Formula of Market Cap: Market Capital = N * P Here, N for the outstanding shares P refers to the closing price of the company's shares. Types of Companies based on Market Cap: - Small-Cap stocks: Up to 500 Crore - Mid-Cap Stocks: From Rs.500 crore up to Rs.7,000 crore - Large-Cap Stocks: From Rs.7,000 crore up to Rs.20,000 crore

Historical Market Cap of Metropolis Healthcare Ltd

Period
Mar '190
Mar '206512
Mar '2111456
Mar '2210422
Mar '236396

* All values are a in crore

×

Historical Revenue of Metropolis Healthcare Ltd

Revenue term means the amount of money a company earns from its primary business activities such as the sales of its products & services. Types of Revenue: 1. Operating revenue: It refers to the income generated from the core business activities, which are sales of goods or services rendered. 2. Non-Operating revenue: It is the income generated from secondary sources unrelated to the primary business. Examples include rents, dividends, interest, and royalty fees. Formula for Revenue: The formula for calculating revenue is based on two goods & services: For goods: Revenue = Avg unit price x Number of Units sold For services: Revenue = Avg unit price x Number of Customers served.

Historical Revenue of Metropolis Healthcare Ltd

Period
Jun '22283
Sep '22305
Dec '22292
Mar '23284
Jun '23280
Sep '23310
Dec '23293
Mar '24334

* All values are a in crore

×

Historical EBITDA of Metropolis Healthcare Ltd

PBIDT stands for Profit Before Interest, Depreciation, and Taxes. It is a financial metric that measures a company's profitability before accounting for interest expenses, depreciation of assets, and taxes. Formula to calculate PBIDT: PBIDT = Net Income + Interest + Depreciation + Taxes or PBIDT = Operating Income + Depreciation + Taxes PBIDT vs EBITDA vs EBIT vs EBT: Here is a brief explanation of the differences: - PBIDT (Profit Before Interest, Depreciation, and Taxes) includes taxes in its calculation, unlike EBITDA. - EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) excludes taxes and interest, focusing on operational performance. - EBIT (Earnings Before Interest and Taxes) excludes interest and taxes, providing a measure of core operational profitability. - EBT (Earnings Before Taxes) includes all operating income but does not account for interest expenses. Conclusion: PBIDT, similar to EBITDA, is a measure of operational profitability but includes taxes in its calculation.

Historical EBITDA of Metropolis Healthcare Ltd

Period
Jun '2272
Sep '2283
Dec '2277
Mar '2372
Jun '2366
Sep '2376
Dec '2367
Mar '2483

* All values are a in crore

×

Historical Net Profit of Metropolis Healthcare Ltd

Net profit is the amount of money a company retains after accounting for all expenses, depreciation, interest, taxes, and other deductions. Net Profit formula is expressed as: Net Profit = Total Revenue - Total Expense Net Profit Margin Ratio: Net Profit Margin Ratio = Net Profit / Total Revenue

Historical Net Profit of Metropolis Healthcare Ltd

Period
Jun '2234
Sep '2240
Dec '2236
Mar '2333
Jun '2329
Sep '2336
Dec '2327
Mar '2437

* All values are a in crore

×

Historical Dividend Payout of Metropolis Healthcare Ltd

Dividend payout refers to the total dividends paid to shareholders relative to the company's earnings. It is a financial measure that determines the percentage of earnings paid out to existing shareholders as dividends. How to calculate Dividend Payout Ratio? The dividend payout ratio formula is as follows: DPR = Dividends paid / Net earnings With the dividend payout ratio, you can understand the company's priorities. It is an important metric that allows you to easily check DPR online.

Historical Dividend Payout of Metropolis Healthcare Ltd

Period
Mar '1976
Mar '2037
Mar '2122
Mar '2221
Mar '2329

* All values are a in %

About Metropolis Healthcare Ltd

About Metropolis Healthcare Ltd

    Dr. Sushil Kanubhai Shah, one of the Promoters, commenced pathology business in January 1980 as a partnership firm in the name of Dr. V. K. Desai's Hospital, having Dr. Kanubhai M. Shah, Dr. Sushil Kanubhai Shah and Dr. Vasant Kalyandas Desai as partners. The partnership was continued by Dr. Sushil Kanubhai Shah, Dr. Kanubhai M. Shah and Dr. Duru Sushil Shah from September 30, 1981 onwards. In June 1989, upon death of Dr. Kanubhai M. Shah, the partnership was continued by Dr. Sushil Kanubhai Shah and Dr. Duru Sushil Shah. Prior to March 18, 1995, Dr. Sushil Kanubhai Shah was also carrying on a business of radioimmunoassay and pathology laboratory on a sole proprietorship basis. On March 20, 1995, the said sole proprietorship business was converted into a partnership with Dr. Sushil Kanubhai Shah, Dr. Duru Sushil Shah and Aparna S. Shah (Rajadhyaksha) as partners, in the name and style of Metropolis Lab. In January 1998, Ameera Sushil Shah was inducted as an additional partner in Metropolis Lab. With effect from February 1, 2002, the business of Metropolis Lab was transferred to Dr. V. K. Desai's Hospital as a going concern. In May 2002, Dr. G. S. K. Velu and Subbulakshmi K. Velu were admitted as partners in Dr. V. K. Desai Hospitals. The name of Dr. V. K. Desai's Hospital was changed to Metropolis Health Services in November 2002. Further, in April 2003, Ameera Sushil Shah, Jaswanti Kanubhai Shah, Sadacharan Gomanthybabu and Gomathybabu Gomathy were admitted as partners in Metropolis Health Services. In July 2003, Metropolis Health Services was converted into a private limited company as Metropolis Health Services (India) Private Limited ('MHSIPL'). The name of MHSIPL was changed to Metropolis Health Services (India) Limited ('MHSIL') pursuant to a Fresh Certificate of Incorporation Consequent upon Change of Name on Conversion to Public Limited Company' on March 1, 2006. In January 2009, MHSIL amalgamated with Pathnet India Private Limited, which was a wholly owned subsidiary of MHSIL. Metropolis Healthcare Ltd (Formerly known as Pathnet India Private Limited) was incorporated at New Delhi on November 10, 2000. The Company is one of the leading diagnostics companies in India. It has widespread presence across 220 cities in India with leadership position in West and South India. Through its widespread operational network, it offers a comprehensive range of clinical laboratory tests and profiles, which are used for prediction, early detection, diagnostic screening, confirmation and/or monitoring of the disease. It also offers analytical and support services to clinical research organizations for their clinical research projects. Presently, it is engaged in the business of providing pathology and related healthcare services. The Company conducts its operations through their laboratory and service network. It has implemented a hub and spoke' model for quick and efficient delivery of services through their widespread laboratory and service network, which covers 197 cities in India. As of December 31, 2018, its laboratory network consists of 115 clinical laboratories, comprising (i) a global reference laboratory ('GRL') located in Mumbai, which is the main hub' and equipped to conduct majority of the tests offered by them; (ii) 14 regional reference laboratories ('RRLs') (out of which four are located outside India), which are equipped to conduct routine, semi-specialized and few specialized tests; (iii) 56 satellite laboratories (out of which one is located outside India), which are equipped to conduct routine and semi-specialized tests; and (iv) 44 express laboratories (out of which five are located outside India), which are equipped to conduct routine tests. Metropolis Healthcare has been awarded the tender by the National Aids Control Organization ('NACO') to collect specimens from 525 government-owned antiretroviral therapy (ART) centers and conduct HIV-1-Viral load tests. It also offers analytical services and support services such as logistics and electronic data interchange ('EDI') to contract research organizations for their clinical research projects. Outside India, it has laboratory operations in Ghana, Kenya, Zambia, Mauritius and Sri Lanka. In addition, it has also entered into agreements with third parties for collection and processing of specimens in Nepal, Nigeria, UAE and Oman. Metropolis' brand is recognized for delivering quality diagnostic and related healthcare tests and services. For instance, it received 'excellence in customer service and delivery' award from Biotrains in 2018, and also received special jury mention for 'service excellence (diagnostic center)' by FICCI at the Healthcare Excellence Awards 2018. In addition, its health campaign was recognized as 'best in health and fitness' in the Digital Campaign Awards 2018 by LH Insights. Metropolis Healthcare Ltd. came out with an Initial Public Offering (IPO) of 13,685,095 equity shares of Face Value of Rs 2/- each of the company for cash at a price of Rs 880 per equity share aggregating Rs 1204.29 Crores, consisting of an offer for sale of 6,272,335 equity shares by Dr. Sushil Kanubhai Shah (the promoter selling shareholder) aggregating to 551.97 Crores and 7,412,760 equity shares by Ca Lotus Investments (the investor selling shareholder) aggregating 652.32 Crores. The face value of equity shares is Rs 2/-each. The IPO was priced at Rs 880 per equity share. During the year 2018-19, the Wholly Owned Subsidiaries viz., Bacchus Hospitality Services and Real Estate Private Limited; Metropolis Healthcare (Chandigarh) Private Limited, Metropolis Healthcare (Jodhpur) Private Limited, Sanket Metropolis Health Services (India) Private Limited, Final Diagnosis Private Limited and Golwilkar Metropolis Health Services (India) Private Limited amalgamated with the Company (Transferee Company) effective from 08 September 2018. Further, the Transferee Company on 08 September 2018 allotted 26,57,731 fully paid up Equity Shares of Rs 10/- each in the ratio of 957,713 Equity Shares of Rs 10/- each to the shareholders of Bacchus for every 10,00,000 Equity Shares of Rs 10/- each held in Bacchus (Pre-bonus and Sub-division). The wellness initiative TruHealth' was launched across 36cities in FY19; launched Medengage, to nurture upcoming medical talent. A wide range of ~3,487 clinical laboratory tests and 530 profiles were offered by Metropolis as of March 2019. The equity shares of Company were listed on BSE Ltd and the National Stock Exchange of India Limited with effect from April 15, 2019. The Company acquired four frontend labs in Surat in FY 2020. It acquired 51% of stake i.e. 5,100 Equity Shares of Shraddha Diagnostic Centre (I) Private Limited (SDCIPL) from the existing shareholders at a consideration of Rs 9,36,30,000/-. It further acquired a total of 550 equity shares of the Target Company (constituting 5.5 % of its Share Capital) on April 7, 2020 for a consideration of Rs 1 Crores. During the year 2020-21, the Company acquired the balance stake of 49% in Raj Metropolis and with effect from November 5, 2020 and as a result, Raj Metropolis became a wholly-owned subsidiary of the Company. In the financial year 2021-22, Metropolis strengthened its operations by adding 16 labs and 506 network centres, as a part of expansion plan of adding 90 labs and 1,800 network centres by FY 24. It acquired the 100% stake in Dr. Ganesan's Hitech Diagnostics Centre Private Limited along with its subsidiary Centralab Healthcare Services Private Limited and post completion of acquisition, Hitech and Centralab became wholly-owned subsidiary and step down wholly owned subsidiary respectively of Company effective 22 Oct' 2021. Similarly, during the year 2021-22, Company had acquired balance stake of 35% of Metropolis Histoexpert Digital Services Private Limited, Subsidiary of the Company from Koninklijke Philips N.V. Post the acquisition, Metropolis Histoxpert became the wholly-owned Subsidiary of the Company with effect from 26 November 2021. During the year 2022-23, the Company launched some complex tests using Next Generation Sequencing (NGS) Technology for Pre-natal screening, Breast Cancer, Bone Marrow Transplant and Allergy Component Testing powered by Artificial Intelligence. In FY 23, it added 14 labs and approximately 548 centers during the year, built a new management team to run the business, integrated the technology offering with Metropolis and executed some cost synergies; further added 83 new tests. During year 2022-23, the subsidiary companies, M/s. Bokil Golwilkar Metropolis Healthcare Private Limited, M/s. Desai Metropolis Health Services Private Limited, M/s. Dr. Patel Metropolis Healthcare Private Limited, M/s. Lab One Metropolis Healthcare Services Private Limited, M/s. Micron Metropolis Healthcare Private Limited, M/s. R. V. Metropolis Diagnostic & Health Care Center Private Limited, M/s. Raj Metropolis Healthcare Private Limited and M/s. Sudharma Metropolis Health Services Private got merged with the Company through the Scheme of Amalgamation, which was made effective from July 11, 2022.

Metropolis Healthcare Ltd News Hub

News

Metropolis Healthcare revenue climbs 13% YoY Q1

The increase in the revenue was driven by patient volume growth approximately 7% and test ...

Read more

09 Jul 202414:53

News

Metropolis Healthcare jumps after Q4 PAT rises 8% YoY to Rs 36.1 cr

Revenue from operations increased 17.7% to Rs 331 crore in Q4 FY24, compared to Rs 282.5 c...

Read more

22 May 202413:03

News

Metropolis Healthcare to hold board meeting

Metropolis Healthcare will hold a meeting of the Board of Directors of the Company on 21 M...

Read more

14 May 202411:18

News

Metropolis hits 52 week high after core biz revenue climbs 15% YoY in Q4

During the period under review, the company’s revenue growth in core business was largely ...

Read more

12 Apr 202410:46

News

Volumes soar at Metropolis Healthcare Ltd counter

Syngene International Ltd, Kaynes Technology India Ltd, Dr Lal Pathlabs Ltd, Sonata Softwa...

Read more

12 Apr 202411:00

News

Metropolis core biz revenue climbs 15% YoY in Q4

During the period under review, the company’s revenue growth in core business was largely ...

Read more

11 Apr 202416:15

Product Composition by Percentage (Revenue)

FAQs for PE of Metropolis Healthcare Ltd

What is Metropolis Healthcare Ltd current share price?

The current market price of Metropolis Healthcare Ltd as of July 16, 2024 is ₹2037.40.

Is Metropolis Healthcare Ltd a good investment?

As per BlinkX Score Metropolis Healthcare Ltd scores 85 in Revenue, 68 in Profitability. However it's advisable to conduct comprehensive research or seek advice from experts to evaluate whether it aligns with your investment objectives.

What are Metropolis Healthcare Ltd's total net assets?

According to Metropolis Healthcare Ltd's most recent financial filings, the company's net assets total ₹314.9 Cr.

Is Metropolis Healthcare Ltd making a profit or loss?

Metropolis Healthcare Ltd's net Profit as of July 16, 2024 is close to ₹127 Cr.
up arrow
50yearstrust

Unlimited trading at just

Rs. 399

Rs. 199